News – Page 1130 – Endpoints News

Genentech doubles down on its PhIII Alzheimer’s campaign for crenezumab

9 years ago

Gates-backed Affinivax grabs $10M upfront and a major league partner for a groundbreaking attempt to beat Pfizer’s ...

9 years ago

Alta Partners sketches plans to raise $200M for its next life sciences venture fund

9 years ago

Gerngross’ Adimab hands over RSV antibodies to Arsanis, a biotech he co-founded in Vienna

9 years ago

Pieris inks a licensing deal for Japan; Kindler joins Pharma Two B board with $30M raise; Ampio plots new pain study

9 years ago

Exelixis, Bristol-Myers mount pivotal study of Cabo/Opdivo combo for frontline kidney cancer

9 years ago

A CRISPR/Cas9 startup launches on the R&D frontier, working on a one-time fix for Duchenne MD

9 years ago

La Jolla’s lead drug hits the primary in PhIII, igniting shares as execs hustle to the FDA

9 years ago

Going big: Biotech vets blast off with Arrakis on a new journey of RNA exploration

9 years ago

Let's not forget why biopharma megamergers are such an awful idea

9 years ago

AstraZeneca gets a thumbs-up for ZS-9 in Europe; Tocagen wins a BTD for brain cancer drug

9 years ago

Struggling Ohr shutters lab after halting enrollment for PhIII wet AMD study

9 years ago

In the wake of a disaster, Cempra shares shoot up on a promising PhIII antibiotic matchup

9 years ago

Merck tees up US/European applications for letermovir after detailing PhIII antiviral success

9 years ago

With hep C franchises languishing, Merck’s MK-3682 goes from blockbuster to bomb

9 years ago

Jackie Fouse is “retiring” from the president’s job at Celgene. Really?

9 years ago

J&J leads a $25M A round for cancer startup; BMJ frets about Trump’s impact on the scientific community

9 years ago

Roche confirms patient death in ACE910 PhIII hemophilia trial, spurring new questions about top blockbuster hopeful

9 years ago

Incyte turns to Penn for a collaboration on next-gen cancer combos

9 years ago

How could you make a Bristol-Myers takeover work without shredding a $5B R&D division?

9 years ago

Genmab outlines a megablockbuster future for itself and J&J as Darzalex gains market traction

9 years ago

Cyclacel unveils a flop in leukemia 2 years after a call on futility, but still won’t give up

9 years ago

The FDA opens an inside track to let Novartis race ahead on Zykadia as Roche rivalry heats up

9 years ago

PhRMA chief plays favorites in singling out Martin Shkreli as a ‘bad actor’; Roche extends antibiotics ...

9 years ago

First page Previous page 1127 1128 112911301131 1132 1133 Next page Last page